Effect of Intravenous Zoledronic Acid on Bone Mineral Density in Osteoporosis Patients
Not Applicable
Recruiting
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0003045
- Lead Sponsor
- Wonkwang University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
? Adults over 50 years old.
? diagnosed as osteoporosis (T-score = 2.5).
Exclusion Criteria
? Creatinin clearance rate < 35mL/min
? Hypersensitivity in Bisphosphonates
? Hypersensitivity of Zoledronic acid
? Serum calcium concentration = 8.4mg/dL
? Pretnant or breast feeding
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone mineral density (BMD) (dual energy X-ray absorptiometry) is used for the diagnosis of osteoporosis in patients over 50 years of age. After intravenous injection of 5 mg of zoledronic acid, the side effects, type and severity are assessed. At the end of the first year, the effect of the zoledronic acid injection is evaluated by re-evaluating the BMD.
- Secondary Outcome Measures
Name Time Method aboratory test (osteocalcin, c-telopeptide, vitamin D, calcium) are evaluated before and one year after the administration of zoledronic acid.